. 2021 Apr 2;147(7):1973–1991. doi: 10.1007/s00432-021-03601-x

Table 1.

Devil facial tumor (DFT) cell lines and treatments

ID #	Sample name	Parent cell line	Treatment
1	DFT1.WT^a	DFT1 C5065	Untreated
2	DFT1.WT + IFNG	DFT1 C5065	5 ng/mL IFNG, 24 h
3	DFT2.WT^RVb	DFT2 RV	Untreated
4	DFT2.WT^RV + IFNG	DFT2 RV	5 ng/mL IFNG, 24 h
5	DFT1.BFP	DFT1 C5065	Transfected with control vector pSBbi-BH
6	DFT1.NLRC5	DFT1 C5065	Transfected with NLRC5 vector pCO1
7	DFT2.WT	DFT2 JV	Untreated
8	DFT2.BFP	DFT2 JV	Transfected with control vector pSBbi-BH
9	DFT2.NLRC5	DFT2 JV	Transfected with NLRC5 vector pCO1
10	DFT1.B2M^−/−	DFT1 C5065	Transfected with B2M targeting vector pAF217
11	DFT1.B2M^−/− + IFNG	DFT1 C5065	Transfected with B2M targeting vector pAF217 and treated with 5 ng/mL IFNG for 24 h
12	DFT1.NLRC5.B2M^−/−	DFT1 C5065	Transfected with NLRC5 vector pCO1 and B2M targeting vector pAF218

^aDFT1.WT data from Patchett et al. (2018) available through European Nucleotide Archive # PRJNA416378

^bDFT2.WT^RV data from Patchett et al. (2020) available through European Nucleotide Archive # PRJEB28680